Capital Research Global Investors Vertex Pharmaceuticals Inc Transaction History

Capital Research Global Investors

$440 Billion
Q1 2025

A detailed history of Capital Research Global Investors transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Capital Research Global Investors holds 14,536,344 shares of VRTX stock, worth $6.34 Billion. This represents 1.6% of its overall portfolio holdings.

Number of Shares

14,536,344

Previous 10,428,951 39.38%

Holding current value

$6.34 Billion

Previous $4.2 Billion 67.81%

% of portfolio

1.6%

Previous 0.9%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	BUY	$402.49 - $513.76 $1.65 Billion - $2.11 Billion	4,107,393 Added 39.38%	14,536,344 $7.05 Billion
Q4 2024 Feb 13, 2025	BUY	$396.64 - $516.74 $566 Million - $737 Million	1,426,746 Added 15.85%	10,428,951 $4.2 Billion
Q3 2024 Nov 13, 2024	BUY	$460.0 - $505.78 $213 Million - $234 Million	462,866 Added 5.42%	9,002,205 $4.19 Billion
Q2 2024 Aug 13, 2024	BUY	$392.81 - $485.53 $1.1 Billion - $1.36 Billion	2,795,457 Added 48.67%	8,539,339 $4 Billion
Q1 2024 May 14, 2024	BUY	$407.69 - $446.08 $887 Million - $971 Million	2,176,218 Added 61.0%	5,743,882 $2.4 Billion
Q4 2023 Feb 13, 2024	BUY	$343.0 - $410.68 $66.9 Million - $80.1 Million	195,080 Added 5.78%	3,567,664 $1.45 Billion
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $105 Million - $113 Million	310,908 Added 10.15%	3,372,584 $1.17 Billion
Q2 2023 Aug 11, 2023	BUY	$314.42 - $351.91 $708 Million - $792 Million	2,251,781 Added 278.03%	3,061,676 $1.08 Billion
Q1 2023 May 15, 2023	BUY	$283.23 - $323.1 $229 Million - $262 Million	809,895 New	809,895 $255 Million
Q4 2020 Feb 12, 2021	SELL	$207.01 - $276.09 $259 Million - $345 Million	-1,250,658 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$255.65 - $303.1 $255 - $303	-1 Reduced -0.0%	1,250,658 $340 Million
Q2 2020 Aug 14, 2020	SELL	$225.48 - $295.8 $1,127 - $1,479	-5 Reduced -0.0%	1,250,659 $363 Million
Q1 2020 May 15, 2020	BUY	$199.77 - $247.81 $2,996 - $3,717	15 Added 0.0%	1,250,664 $298 Million
Q4 2019 Feb 18, 2020	BUY	$166.71 - $223.91 $63,183 - $84,861	379 Added 0.03%	1,250,649 $274 Million
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $3,657 - $4,115	22 Added 0.0%	1,250,270 $212 Million
Q2 2019 Aug 14, 2019	BUY	$164.61 - $190.37 $40,823 - $47,211	248 Added 0.02%	1,250,248 $229 Million
Q1 2019 May 15, 2019	SELL	$163.73 - $194.7 $133 Million - $159 Million	-815,018 Reduced 39.47%	1,250,000 $230 Million
Q4 2018 Feb 14, 2019	SELL	$151.91 - $192.21 $89.6 Million - $113 Million	-590,000 Reduced 22.22%	2,065,018 $342 Million
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $445 Million - $512 Million	2,655,018 New	2,655,018 $512 Million

Others Institutions Holding VRTX

# of Institutions

1,830

Shares Held

233M

Call Options Held

1.38M

Put Options Held

1.08M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $112B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Research Global Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital Research Global Investors with notifications on news.

Account

Capital Research Global Investors Vertex Pharmaceuticals Inc Transaction History